CryoLife completed the acquisition of Ascyrus Medical for $200m.

CryoLife, a cardiac and vascular surgery company focused on aortic disease, completed the acquisition of Ascyrus Medical, a developer of the world's first aortic arch remodeling device used for the treatment of acute Type A aortic dissections, for $200m. "We believe the addition of the AMDS to our product offerings will make a meaningful contribution to our future growth as it gives us immediate access to the combined $100+m EU and Canadian markets and has the potential to expand our worldwide addressable market by approximately $540m. AMDS is another highly differentiated device that, when included in our commercial channel, will further solidify our position as a global leader in aortic repair, as it will immediately strengthen our highly competitive product portfolio in Europe," Pat Mackin, CryoLife Chairman, President, and Chief Executive Officer.